Alyeska Investment Group, L.P. In8 Bio, Inc. Transaction History
Alyeska Investment Group, L.P.
- $18 Billion
- Q3 2024
A detailed history of Alyeska Investment Group, L.P. transactions in In8 Bio, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 434,809 shares of INAB stock, worth $147,835. This represents 0.0% of its overall portfolio holdings.
Number of Shares
434,809
Previous 641,008
32.17%
Holding current value
$147,835
Previous $544,000
78.49%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding INAB
# of Institutions
26Shares Held
7.57MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD1.67MShares$569,3760.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$484,1240.0% of portfolio
-
683 Capital Management, LLC New York, NY1.35MShares$459,1030.03% of portfolio
-
Sigma Planning Corp Ann Arbor, MI851KShares$289,4350.01% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT829KShares$281,9190.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $8.33M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...